Lymphoma

13 protocols meet the specified criteria.

  • A051901

    Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

  • A211901

    Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

  • CCTL019B2003I

    Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)

  • EZH-302

    SYMPHONY-1: A Phase 1B/3 Double-blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat/EPZ-6438 or Placebo in Combination with Lenalidomide plus Rituximab (R^2) in Subjects with Relapsed/Refractory Follicular Lymphoma

  • GO43878

    A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma

  • GO44145

    SKYGLO: A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Safety and Efficacy of Glofitimab (RO7082859) in Combination with Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma

  • INCA-34176-357

    A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  • JCAR017-EAP-001

    Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

  • KT-US-472-0141

    Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication

  • NCBP6637-01

    A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

  • WVU010922

    Prospective Evaluation of Xerava (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia